Introduction: Hairy cell leukemia is a rare B-cell lymph proliferation with long-term survivals, in general. Although therapeutic possibilities have progressed over time, many patients have recurrences and the disease can become resistant to treatment. Discovering the BRAF V600E and other genetic mutations and some pathogenetic mechanisms disruptions open new therapeutic horizons.
Case presentation: We present a female patient to which the disease has been monitored for 14 years, during which she has been treated with alpha-interferon, cladribine and ituximab. The monitorization and conduct of such patients are discussed, and an analysis of the therapeutic possibilities at this stage is performed, which can be useful for physicians and researchers.
Conclusion: An individual assessment of patient at diagnosis and during evolution is needed to determine which drug or drug combination is indicated and how many therapeutic lines are needed.
Published on: Aug 14, 2015 Pages: 4-7
Leeds Beckett University, UK
Archives of Community Medicine and Public Health
National Center for Toxicological Research (NCTR)/FDA, USA
Global Journal of Anesthesiology
Arghya Narayan Banerjee
Yeungnam University, South Korea
International Journal of Nanomaterials, Nanotechnology and Nanomedicine
Dr. Pierre Guertin
Laval University, Canada
Archive of Gerontology and Geriatrics Research
Samy I. McFarlane
State University of New York, Downstate Medical Centre, Brooklyn, New York, USA
International Journal of Clinical Endocrinology and Metabolism